Alzinova appoints Mangold Fondkommission as new liquidity provider

Alzinova AB (”Alzinova” or the ”Company”) has appointed Mangold Fondkommission AB (”Mangold”) as liquidity provider for the Company’s shares, listed on Nasdaq First North Growth Market (”Nasdaq First North”). The purpose of the liquidity provider, is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on 8 June, 2022.

A liquidity provider aims to provide a more correct price picture in the Company’s share. Mangold will fulfil its assignment as liquidity provider to ensure the possibility of trading in Alzinova’s share every day by continuously placing trading records on each purchase and sales page in the order book.

For further information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
E-mail: kristina.torfgard@alzinova.com

About Alzinova AB
Alzinova is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid-beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com